Kruseová J, Mottl H, Kodet R, Mrácek J, Matejovský Z ml, Schovanec J, Snajdauf J, Rygl M, Lisková I, Kabítková E, Malis J, Sumerauer D, Drahokoupilová E, Ganevová M, Smelhaus V, Starý J
Klinika detské hematologie a onkologie 2. LF UK a FN Motol, Praha.
Klin Onkol. 2009;22(4):168-75.
We evaluated the therapeutic results in 44 patients (17 girls and 27 boys) with osteosarcoma from 1997 to 2006.Their average age was 12.8 years (2.5-20.2). 41 patients had localised disease and 3 had primary metastases.
We treated our 44 patients using CCG 7921 POG 9351 INT 0133, the therapeutic protocol of the North American cooperative Children's Oncology Group.The median of the follow up was 5.5 years (2-11 years).
40 patients went into complete remission. 19 patients suffered relapses. Of these, 17 patients died - 15 progressed, 1 died due to treatment-related toxicity, 1 died due to secondary acute myeloid leukaemia. As a whole, the patients had a 5-year overall survival rate (OS) of 58.4% and a 5-year event free survival rate (EFS) of 46.7%. The patients with localised extremity osteosarcoma (n = 40) had a 5-year EFS rate of 51%. The patients with good histological response (n = 22) had a 5-year EFS rate of 63.6%, while patients with poor histological response (n = 18) achieved a 5-year EFS rate of 30.5% (p = 0.009).
The results of treatment of patients with localised extremity osteosarcoma and patients with good histological response to preoperative treatment were very good. The prognosis of patients with axial localisation and metastatic involvement was poor.
我们评估了1997年至2006年期间44例骨肉瘤患者(17例女孩和27例男孩)的治疗结果。他们的平均年龄为12.8岁(2.5 - 20.2岁)。41例患者为局限性疾病,3例有原发性转移。
我们采用北美儿童肿瘤协作组的治疗方案CCG 7921 POG 9351 INT 0133对44例患者进行治疗。随访时间中位数为5.5年(2 - 11年)。
40例患者完全缓解。19例患者复发。其中,17例患者死亡 - 15例病情进展,1例死于治疗相关毒性,1例死于继发性急性髓系白血病。总体而言,患者的5年总生存率(OS)为58.4%,5年无事件生存率(EFS)为46.7%。局限性肢体骨肉瘤患者(n = 40)的5年EFS率为51%。组织学反应良好的患者(n = 22)的5年EFS率为63.6%,而组织学反应较差的患者(n = 18)的5年EFS率为30.5%(p = 0.009)。
局限性肢体骨肉瘤患者以及术前治疗组织学反应良好的患者治疗效果非常好。轴向定位和转移受累患者的预后较差。